Sponsor interactions with the US Food and Drug Administration appear to be running as well as could be expected, despite some minor changes, as the FDA has adapted to mass-teleworking conditions under the coronavirus pandemic.
Conversations may be different, even in situations when a teleconference would be a routine event. Attorney Kurt Karst, a director...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?